Targets › CD44
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. (UniProt, P16070)
Open in Phaseline: the race on CD44, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tasly Pharmaceuticals | P134 cells CD44/CD133 dual-targeting CAR-T cells | CD44, CD133 | Phase 1 | Recurrent Glioblastoma IDH Wildtype | Feb 2028 |
Recurrent Glioblastoma IDH Wildtype (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.